Global CDMO Growth Hovione is a large international pharma CDMO with revenue exceeding $10B and a broad footprint across Europe, the USA, and Asia, presenting scalable outsourcing opportunities for drug substances, intermediates, and finished products to partners worldwide.

Oral Solid Focus Recent expansions increase commercial scale tablet manufacturing capacity in Loures, Portugal by approximately 25% and further investments in a new Seixal unit signal a strong push in oral solid dosage manufacturing, creating cross-sell potential for tablet development, scale-up, and continuous manufacturing services.

Continuous Manufacturing Hovione emphasizes continuous manufacturing alongside traditional batch processes and hosts industry forums, indicating a readiness to collaborate on advanced, cost-efficient production methods and to offer consulting, process development, and scalable implementation for clients exploring continuous tech.

Strategic Talent & Tech A diverse global team and strong digital infrastructure (iCIMS, Qlik, GitHub, CrowdStrike, Active Directory) suggest Hovione can be a partner for pharmaceutical companies seeking digitalization in R&D, regulatory, and manufacturing workflows, including data integration and secure collaboration platforms.

Leadership & Expansion Upcoming leadership change with a new CEO appointment and ongoing facility expansions in New Jersey, Loures, and Seixal signal aggressive growth and potential for multi-region, multi-asset outsourcing deals, including late-stage development to commercial supply partnerships.